Results
1
-
10
of
86
<
1
2
3
...
8
9
>
Gulland A.
Cystic fibrosis drug is not cost effective, says NICE.
,
BMJ (Clinical research ed.)
Quon BS; Rowe SM.
New and emerging targeted therapies for cystic fibrosis.
,
BMJ (Clinical research ed.)
Desch M.
[Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
,
Medizinische Monatsschrift fur Pharmazeuten
Nau JY.
[Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
,
Revue medicale suisse
Mayor S.
Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
,
BMJ (Clinical research ed.)
Bertoncini E; Colomb-Lippa D.
Pulmonology: CFTR modulators for cystic fibrosis.
,
JAAPA : official journal of the American Academy of Physician Assistants
Riquelme SA; Hopkins BD; Wolfe AL; DiMango E; Kitur K; Parsons R; Prince A.
Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity.
,
Immunity
[DOI: 10.1016/j.immuni.2017.11.010]
Hudson RP; Dawson JE; Chong PA; Yang Z; Millen L; Thomas PJ; Brouillette CG; Forman-Kay JD.
Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface.
,
Molecular pharmacology
[DOI: 10.1124/mol.117.108373]
Loo TW; Clarke DM.
Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
,
Biochemical pharmacology
[DOI: 10.1016/j.bcp.2017.03.020]
Egan ME.
Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR.
,
American journal of respiratory and critical care medicine
[DOI: 10.1164/rccm.201611-2290ED]
<
1
2
3
...
8
9
>